FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

7

Transaction(s) (Instr. 4)

100,000

D

ĪĒ

							-								ONB	APPRO	VAL
Section obligat	this box if no lo n 16. Form 4 or tions may conti ction 1(b).		NT OF CHANGES IN BENEFICIAL OWNERSHIP									Estim	OMB Number: 32 Estimated average burden hours per response:				
Instruc	cuon r(b).			File		tion 30(h) of the l						4					1
1. Name and Address of Reporting Person [*] Evanson Jeff					2. Issuer Name and Ticker or Trading Symbol Outlook Therapeutics, Inc. [OTLK]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner Officer (give title Other (specify				vner
(Last) (First) (Middle) C/O OUTLOOK THERAPEUTICS, INC. 485 ROUTE 1 SOUTH, BLDG F, SUITE 320					3. Date of Earliest Transaction (Month/Day/Year) 03/31/2022								X Oncer (give title Confer (specify below) below) Chief Commercial Officer				
						4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable Line)				
(Street) ISELIN NJ 08830											- I - '	X Form filed by One Reporting Person Form filed by More than One Reporting					
(City)	(5	State)	(Zip)										Person				
		Т	able I - Non	-Deriv	ative S	ecurities Aco	qui	ired,	Disp	osed of	f, or Bene	ficially	Owned				
1. Title of Security (Instr. 3) 2. Trans Date (Month/					action Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year	Transaction Dispose Code (Instr.			4. Securiti Disposed	ties Acquired (A) or I Of (D) (Instr. 3, 4 an		d 5) 5. Amount of Securities Beneficially Owned Follow Reported		Form:	Direct Indirect tr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
								Code	v	Amount	(A) or (D)	Price	Transaction				(1150. 4)
						curities Acqu IIs, warrants							wned				
1. Title of Derivative Security (Instr. 3) 2. 3. Transaction Date Price of Derivative Security 3A. Deemed Execution Date (Month/Day/Year) 1. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date (Month/Day/Year)			Cod	nsaction de (Instr.	Derivative E		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownershij (Instr. 4)	

1. Represents the number of shares that vested under a performance-based stock option grant based on the Issuer's satisfaction of certain performance criteria. In light of the performance-based vesting conditions of the option, such shares were not reportable under Section 16 until vesting was determined, which occurred on March 31, 2022. The vested shares represents the first of three possible vesting events of the total number of shares subject to the option. The remaining shares subject to the option will vest only upon the satisfaction of additional performance vesting criteria. 2. Fully vested and immediately exercisable.

Stock Option (Right to

Buy)

\$1.44

Explanation of Responses:

Remarks:

/s/ Lawrence Kenyon, Attorney-04/04/2022

\$0.00

in-Fact

Expiration Date

12/21/2031

Date Exercisable

(2)

(D)

Title

Common

Stock

Amount Number of Shares

100,000

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

03/31/2022

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

v

(A)

100,000⁽¹⁾

Code

Α

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.